245 related articles for article (PubMed ID: 33835054)
1. Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia.
Naber SK; Almadi MA; Guyatt G; Xie F; Lansdorp-Vogelaar I
Saudi J Gastroenterol; 2021; 27(4):208-216. PubMed ID: 33835054
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
3. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
4. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
6. Optimising colorectal cancer screening in Shanghai, China: a modelling study.
Cenin D; Li P; Wang J; de Jonge L; Yan B; Tao S; Lansdorp-Vogelaar I
BMJ Open; 2022 May; 12(5):e048156. PubMed ID: 35577474
[TBL] [Abstract][Full Text] [Related]
7. Would initiating colorectal cancer screening from age of 45 be cost-effective in Germany? An individual-level simulation analysis.
Lwin MW; Cheng CY; Calderazzo S; Schramm C; Schlander M
Front Public Health; 2024; 12():1307427. PubMed ID: 38454984
[TBL] [Abstract][Full Text] [Related]
8. Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness.
van Hees F; Saini SD; Lansdorp-Vogelaar I; Vijan S; Meester RG; de Koning HJ; Zauber AG; van Ballegooijen M
Gastroenterology; 2015 Nov; 149(6):1425-37. PubMed ID: 26253304
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.
Gini A; Zauber AG; Cenin DR; Omidvari AH; Hempstead SE; Fink AK; Lowenfels AB; Lansdorp-Vogelaar I
Gastroenterology; 2018 Feb; 154(3):556-567.e18. PubMed ID: 29102616
[TBL] [Abstract][Full Text] [Related]
10. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study.
Buskermolen M; Cenin DR; Helsingen LM; Guyatt G; Vandvik PO; Haug U; Bretthauer M; Lansdorp-Vogelaar I
BMJ; 2019 Oct; 367():l5383. PubMed ID: 31578177
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors.
Gini A; Meester RGS; Keshavarz H; Oeffinger KC; Ahmed S; Hodgson DC; Lansdorp-Vogelaar I
J Natl Cancer Inst; 2019 Nov; 111(11):1161-1169. PubMed ID: 30980665
[TBL] [Abstract][Full Text] [Related]
12. Efficient organized colorectal cancer screening in Shenzhen: a microsimulation modelling study.
Zhu M; Zhong X; Liao T; Peng X; Lei L; Peng J; Cao Y
BMC Public Health; 2024 Mar; 24(1):655. PubMed ID: 38429684
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test.
Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N
J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780
[TBL] [Abstract][Full Text] [Related]
14. Optimizing screening with faecal immunochemical test for both sexes - Cost-effectiveness analysis from Finland.
Heinävaara S; Gini A; Sarkeala T; Anttila A; de Koning H; Lansdorp-Vogelaar I
Prev Med; 2022 Apr; 157():106990. PubMed ID: 35150749
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of colorectal cancer screening in Slovakia.
Babela R; Orsagh A; Ricova J; Lansdorp-Vogelaar I; Csanadi M; De Koning H; Reckova M
Eur J Cancer Prev; 2022 Sep; 31(5):415-421. PubMed ID: 34789653
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Screening Colonoscopy in Iranian High Risk Population.
Javadinasab H; Daroudi R; Salimzadeh H; Delavari A; Vezvaie P; Malekzadeh R
Arch Iran Med; 2017 Sep; 20(9):564-571. PubMed ID: 29048918
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China.
Ren Y; Zhao M; Zhou D; Xing Q; Gong F; Tang W
Front Public Health; 2022; 10():952378. PubMed ID: 36033786
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
Wong CK; Lam CL; Wan YF; Fong DY
BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
